RBC Capital raised the firm’s price target on Catalent (CTLT) to $58 from $55 and keeps an Outperform rating on the shares ahead of its Q2 results next week. The recent investor conversations have centered on expected contributions from Sarepta Therapeutics (SRPT) and GLP-1s in FY25 and beyond given their importance to both longer-range earnings and the activist/M&A angle, though its unlikely that there will be meaningful updates on either, the analyst tells investors in a research note. Investor focus will likely be on FY24 EBITDA progression vs. guidance and the extent to which Catalent management is continuing to “control the controllables”, the firm added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CTLT: